Upstream Bio (UPB) Net Income towards Common Stockholders (2023 - 2026)

Upstream Bio's Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$61.8 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 126.57% year-over-year to -$61.8 million in Q1 2026; TTM through Mar 2026 was -$178.0 million, a 98.49% decrease from a year earlier, with the FY2025 full-year figure at -$143.4 million, down 87.76% from the prior year.
• Net Income towards Common Stockholders retreated to -$61.8 million in Q1 2026 per UPB's latest filing, from -$42.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$6.3 million in Q3 2023 and bottomed at -$61.8 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$21.8 million (2024), against an average of -$27.5 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 45.42% in 2024; the steepest drop was 236.37% in 2024.
• Year by year, Net Income towards Common Stockholders stood at -$15.0 million in 2023, then tumbled by 45.42% to -$21.8 million in 2024, then tumbled by 94.86% to -$42.5 million in 2025, then tumbled by 45.52% to -$61.8 million in 2026.
• Per Business Quant, the three latest UPB Net Income towards Common Stockholders figures stand at -$61.8 million (Q1 2026), -$42.5 million (Q4 2025), and -$33.7 million (Q3 2025).